secwatch.observer — SEC 8-K summary
======================================

Issuer:     Poseida Therapeutics, Inc. (—)
CIK:        0001661460
Form:       8-K
Filed at:   2023-10-10T23:59:59+00:00
Accession:  0001193125-23-252990
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Poseida announces CEO transition; Kristin Yarema to become CEO, Mark Gergen to become Executive Chairman
--------------------------------------------------------------------------------

- Kristin Yarema, currently President, Cell Therapy, appointed President and CEO effective January 1, 2024.
- Mark Gergen, current President and CEO, will become Executive Chairman of the Board on the same date.
- Amended employment agreements to be entered with Dr. Yarema and Mr. Gergen prior to effective date.
- No material transactions or family relationships disclosed between Dr. Yarema and the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661460/000119312523252990/0001193125-23-252990-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661460/000119312523252990/d472927d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-252990

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer